Life Sciences Strategy: one year on
10 Dec 2012
Prime Minister David Cameron and Science Minister David Willetts have launched a report on the Strategy for UK Life Sciences One Year On.
The report shows that the UK has generated more than £1bn on industry and private sector investment within 12 months. This includes
- £ 500 m from GSK to build its first new manufacturing plant in almost 40 years at Ulverston in Cumbria and invest more in its two sites at Montrose and Irvine in Scotland as a direct response to the introduction of the Patent Box;
- £ 25 m leveraged in from the private sector to bridge the ‘Valley of Death’ adding to a government commitment of £49m to 64 projects through the Biomedical Catalyst; and,
- £ 294 m through the UK Research Partnership Investment Fund (UK RPIF) from businesses and charities.
Real progress has been made working closely with companies across the sector to ensure the measures in the strategy are making a real difference to their work and their decisions to invest in and remain in the UK.
This includes investing £1bn per annum through the National Institute for Health Research, which includes £500m in our translational research infrastructure in the NHS to boost networks between academia, industry and the NHS.
Revolutionising the fight against cancer
David Cameron also announced that The UK will be the first country in the world to introduce to introduce high-tech DNA mapping for cancer patients and those with rare diseases, within the NHS. Up to 100,000 patients over three to five years will have their whole genome – their personal DNA code –sequenced.
The genome profile will give doctors a new, advanced understanding of a patient’s genetic make-up, condition and treatment needs, ensuring they have access to the right drugs and personalised care far quicker than ever before.
It will also help to develop life-saving new drugs, treatments and scientific breakthroughs, which experts predict could significantly reduce the number of premature deaths from cancer within a generation.
The Government has earmarked £100 million:
- to train a new generation of British genetic scientists to lead on the development of new drugs, treatments and cures, building the UK as the world leader in the field. And train the wider healthcare community in harnessing this technology
- to pump-prime DNA sequencing for cancer and rare inherited diseases; and
to build the NHS data infrastructure to ensure that this new technology leads to better care for patients.
Minister for Science and Universities David Willetts said:
“Life sciences is one of the most truly international sectors – so if we are to continue to be a world player and compete in the global race we must do everything we can to support it
”In the past year, our initiatives have attracted more than £1 billion of private sector investment to the UK. We can see clear evidence the UK is succeeding in creating the right environment to attract global investment to our shores and continue to be world leader in life sciences.
“I am announcing today that we are committing a further £100 million to support this sector out of the extra money for science announced by the chancellor in his Autumn Statement”
David Cameron launched the Strategy for UK Life Sciences in December 2011. Health Life Sciences is one of the 11 sectors that have been prioritised as part of the Government's industrial strategy. The UK has one of the strongest and most productive life sciences sectors in the world, generating turnover of over £50 billion and employing 167,500 people in over 4500 companies.